Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Zasowski, Evan J ^a   Trinh, Trang D ^a   Claeys, Kimberly C ^a,b   Casapao, Anthony M ^a,c   Sabagha, Noor ^a   Lagnf, Abdalhamid M ^a   Klinker, Kenneth P ^d   Davis, Susan L ^a,e   Rybak, Michael J ^a,f,g  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c HUSSON UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DETROIT MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Beta lactam; Bone and joint infection; Daptomycin; Infective endocarditis; MRSA; Pneumonia; Treatment failure; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE FOSAMIL; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOODSTREAM INFECTION; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY FAILURE; CHRONOPHARMACOLOGY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; NEUTROPENIA; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BACTEREMIA; CLINICAL TRIAL; DRUG EFFECTS; ENDOCARDITIS; KAPLAN MEIER METHOD; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL;

AGED; BACTEREMIA; CEPHALOSPORINS; DAPTOMYCIN; ENDOCARDITIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 85011003433     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02015-16     Document Type: Article

References (39)

1. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, Lessa FC, Lynfield R, Nadle J, Petit S, Ray SM, Schaffner W, Townes J, Fridkin S, Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. 2013. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 173:1970-1978. https://doi.org/10.1001/jamainternmed.2013.10423.
2. Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG, Jr, Hellmich M, Hopkins S, Kern WV, Llewelyn MJ, Rieg S, Rodriguez-Bano J, Scarborough M, Seifert H, Soriano A, Tilley R, Torok ME, Weiss V, Wilson AP, Thwaites GE. 2014. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect 68:242-251. https://doi.org/10.1016/j.jinf.2013.10.015.
3. Lodise TP, McKinnon PS. 2005. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 52:113-122. https://doi.org/10.1016/j.diagmicrobio.2005.02.007.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. 2003. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53-59. https://doi.org/10.1086/345476.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18-e55. https://doi.org/10.1093/cid/ciq146.
6. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755-771. https://doi.org/10.1093/cid/cir935.
7. Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. 2013. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bloodstream infection. Antimicrob Agents Chemother 57:4252-4259. https://doi.org/10.1128/AAC.00380-13.
8. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665. https://doi.org/10.1056/NEJMoa053783.
9. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51-58. https://doi.org/10.1093/cid/cir764.
10. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. 2013. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 56:1562-1569. https://doi.org/10.1093/cid/cit112.
11. Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. 2016. Propensity matched analysis of early daptomycin versus vancomycin for methicillin-resistant S. aureus bloodstream infections: daptomycin improves outcomes regardless of vancomycin MIC. Antimicrob Agents Chemother 60:5841-5848. https://doi.org/10.1128/AAC.00227-16.
12. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149-2152. https://doi.org/10.1086/430352.
13. Barber KE, Ireland CE, Bukavyn N, Rybak MJ. 2014. Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther 3:35-43. https://doi.org/10.1007/s40121-014-0023-0.
14. Sharma M, Riederer K, Chase P, Khatib R. 2008. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 27:433-437. https://doi.org/10.1007/s10096-007-0455-5.
15. Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Martin C, Lopez-Medrano F, de Gopegui ER, Blanco JR, Garcia-Pardo G, Calbo E, Montero M, Granados A, Jover A, Duenas C, Pujol M. 2014. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother 69:568-571. https://doi.org/10.1093/jac/dkt396.
16. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother 57:3178-3181. https://doi.org/10.1128/AAC.00484-13.
17. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. 2014. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:2541-2546. https://doi.org/10.1128/AAC.02371-13.
18. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, II. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67:1267-1270. https://doi.org/10.1093/jac/dks006.
19. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. 2013. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 19:42-49. https://doi.org/10.1007/s10156-012-0449-9.
20. Polenakovik HM, Pleiman CM. 2013. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 42:450-455. https://doi.org/10.1016/j.ijantimicag.2013.07.005.
21. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, Alfandari S, Stahl JP. 2014. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 69:2010-2013. https://doi.org/10.1093/jac/dku085.
22. Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. 2014. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis 1:ofu046. https://doi.org/10.1093/ofid/ofu046.
23. Paladino JA, Jacobs DM, Shields RK, Taylor J, Bader J, Adelman MH, Wilton GJ, Crane JK, Schentag JJ. 2014. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents 44:557-563. https://doi.org/10.1016/j.ijantimicag.2014.07.024.
24. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. 2014. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 36:1317-1333. https://doi.org/10.1016/j.clinthera.2014.05.061.
25. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. 2015. Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study. Crit Care 19:312. https://doi.org/10.1186/s13054-015-1029-z.
26. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E. 2000. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 30:368-373. https://doi.org/10.1086/313650.
27. Levine DP, Fromm BS, Reddy BR. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674-680. https://doi.org/10.7326/0003-4819-115-9-674.
28. Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. 2014. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 92:139-149. https://doi.org/10.1007/s00109-013-1100-7.
29. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:66-73. https://doi.org/10.1128/AAC.01586-12.
30. Barber KE, Rybak MJ, Sakoulas G. 2015. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother 70:311-313. https://doi.org/10.1093/jac/dku322.
31. Clinical and Laboratory Standards Institute. 2014. M100-S24: performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
32. Canut A, Isla A, Rodriguez-Gascon A. 2015. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 45:399-405. https://doi.org/10.1016/j.ijantimicag.2014.12.023.
33. LaVie KW, Anderson SW, O'Neal HR, Rice TW, Saavedra TC, O'Neal CS. 2016. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother 60:264-269. https://doi.org/10.1128/AAC.01471-15.
34. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332. https://doi.org/10.1016/j.ajic.2008.03.002.
35. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381. https://doi.org/10.1016/j.jbi.2008.08.010.
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. https://doi.org/10.1016/0021-9681(87)90171-8.
37. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: a severity of disease classification system. Crit Care Med 13:818-829. https://doi.org/10.1097/00003246-198510000-00009.
38. Stevens V, Lodise TP, Tsuji B, Stringham M, Butterfield J, Dodds Ashley E, Brown K, Forrest A, Brown J. 2012. The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 33:558-564. https://doi.org/10.1086/665731.
39. National Cancer Institute Cancer Therapy Evaluation Program. 1999. Common toxicity criteria manual. Version 2.0. National Cancer Institute, Rockville, MD. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcmanual-v4-10-4-99.pdf.